Important note

This AI stock analysis for Angiodynamic is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Angiodynamic - AI Stock Analysis

Analysis generated July 17, 2024

Angiodynamic is a medical device company specializing in the design and manufacturing of products for minimally invasive vascular access, surgery, peripheral vascular disease, and oncology. The company's product portfolio includes a variety of catheters, angiographic products, and other medical devices. Angiodynamic has a significant presence in the healthcare sector, serving hospitals and healthcare providers worldwide.

Fundamental Analysis

Angiodynamic's financials present a mix of troubling metrics. The revenue for the last quarter was $76 million, marking a decrease of 5.06% compared to the previous quarter and 5.50% from the same quarter last year. This downward trend indicates potential challenges in market demand or competitive pressures.

Net income for the last quarter was reported at a staggering $188 million. However, this figure represents a decrease of 546.30% compared to the previous quarter and 1,879.29% compared to the same quarter last year. These sharp declines point towards severe financial strain, possibly stemming from increased operational costs or reduced margins.

EBITDA for the last quarter stood at $193 million, showcasing a troubling decrease of 2,878.38% compared to the previous quarter and a dramatic fall of 17,570.83% compared to the same quarter last year. Such drastic decreases in EBITDA could signal fundamental issues in the company's core operational efficiency.

Additionally, the current Price to Earnings (P/E) ratio for Angiodynamic is 41.4. A P/E ratio this high may suggest that the stock is overvalued and could hint at a bearish outlook among investors.

Technical Analysis

Angiodynamic's current stock price is $7.51, reflecting a 27.50% increase from a month ago and indicating a short-term positive trend. Conversely, the stock price has decreased by 22.90% compared to a year ago, highlighting potential long-term concerns.

The bullish trend is further supported by the current 10-day Simple Moving Average (SMA10) of 6.18, which is higher than the previous SMA10 of 5.99. This suggests an upward trend in the stock's price movement.

Moreover, the Relative Strength Index (RSI) is at 22.6, indicating an oversold condition. RSI values below 30 suggest that the stock might be undervalued and could be poised for a rebound, implying a bullish outlook in the short term.

Alternative Data Analysis

From an alternative data perspective, Angiodynamic has some concerning indicators. The company has 21 open positions according to data from job boards, which is a 38% decrease in the last couple of months. This reduction in job postings might suggest efforts to cut costs or improve margins, indicating potential financial distress rather than growth.

The employee sentiment regarding business outlook is neutral, which does not provide strong confidence in the company's future prospects from an insider's viewpoint.

Regarding customer acquisition, Angiodynamic has an estimated 19,000 visitors to their webpage with no meaningful change in the last few months. Similarly, the company's Twitter page has 1,500 followers, again with no significant increase or decrease in recent months. These stagnant metrics indicate a lack of growth in customer engagement and brand outreach.

Furthermore, AltIndex's AI score for Angiodynamic, which integrates various data points to forecast stock performance, stands at 35. This score represents a clear 'sell' signal, suggesting that the aggregated data points towards a bearish outlook.

Conclusion

Based on the comprehensive analysis above, Angiodynamic exhibits several red flags across different analytical dimensions. The declines in revenue, net income, and EBITDA reflect underlying financial challenges, while the high P/E ratio suggests potential overvaluation. Although the stock shows short-term positive movements and an oversold RSI, the long-term trend remains concerning.

Alternative data indicators further solidify this cautious outlook with decreased job postings and stagnant customer engagement metrics. Given these factors, accompanied by a sell signal from AltIndex's AI score, investors should approach Angiodynamic stock with caution.

Recommendation: Sell or avoid buying Angiodynamic stock until more favorable financial and alternative data indicators emerge.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.